Sept 28 (Reuters) - AEterna Zentaris Inc AEZ.TO :
* Says zoptarelin doxorubicin meets phase 2 primary endpoint
* Says forty-four percent of patients demonstrated improvement of pain score at
12 weeks
* Says zoptarelin doxorubicin demonstrated good tolerability in the study
* Source text for Eikon ID:nCNWmx3Rha
* Further company coverage AEZ.TO